Építés alatt – nem éles oldal
Belépés
Résztvevőt keresFázis nélkül

Cardiovascular Disease Progression in Survivors of Community Acquired Pneumonia and Lung Infection by Covid-19.

A legfontosabb adatok

Ki végzi
Hellenic Institute for the Study of Sepsis
Hol
Görögország19 helyszín, 1 országbanVálassz országot a helyszínekhez
Azonosító
Állapot
Toboroz
Résztvevők
650 fő, tervezett
Kezdés
2024. nov. 8.
Várható befejezés
2028. jún. 8.
A vizsgálat típusa
Megfigyeléses, 4 csoport
A vizsgált kezelések
  • Blood samples and Oropharyngeal swab
  • Six-minute walk test, Spirometry, ECG, Heart ultrasound and cardiopulmonary exercise stress testing, Completion of questionnaires of symptoms
A regiszteradat frissítve
2026. november 6.

Ki vehet részt

Életkor
18 év felett
Nem
Nők és férfiak
Egészséges önkéntesek
Részt vehetnek

A regiszter feltételei, szó szerint

Mind a 29 feltétel megnézéseKevesebb

Ki vehet részt

  • Group A (healthy controls)
  • Adults (18 years or more) of both genders (Female/Male: 50/50 ratio)
  • No history of severe pneumonia (sCAP, COVID-19 or HAP)
  • Presence of no or one of the following comorbidities: obesity (defined as body mass index over 35 kg/m2), type 2 diabetes mellitus, hypercholesterolemia, essential arterial hypertension, or familial history of CVD; Group B (CVRD controls)
  • Adults (18 years or more) of both genders (Female/Male ratio: 50/50)
  • No history of severe pneumonia (sCAP, COVID-19 or HAP)
  • At least two of the following comorbidities: obesity (defined as body mass index over 35 kg/m2), type 2 diabetes mellitus, hypercholesterolemia, essential arterial hypertension, or familial history of CVD; Group C (COVID-19 survivors)
  • Adults (18 years or more) of both genders (Female/Male ratio: 50/50)
  • Survivors from severe COVID-19 pneumonia at hospital discharge; all patients had consolidation in chest X-ray or chest computed tomography during acute infection and were treated for pneumonia
  • SoC treatment for acute COVID-19 with dexamethasone; Group D (sCAP survivors)
  • Adults (18 years or more) of both genders
  • Survivors from sCAP pneumonia; these patients may be either hospitalized in the ward with pO2FiO2 ratio less than 300 or require admission and hospitalization in the Intensive Care Unit
  • SoC treatment for sCAP with antibiotics

Ki nem vehet részt

  • Any other co-existing disorder generating CVRD symptoms
  • Any other co-existing disorder generating CVRD symptoms
  • Pregnancy or lactation; Group C (COVID-19 survivors)
  • Medical history of severe congestive heart failure (Stage III-IV)
  • Medical history of stage III or IV dyspnoea according to the New York Heart Association classification before the acute COVID-19
  • Medical history of severe congestive heart failure (Stage III-IV)
  • Medical history of stage III or IV dyspnoea according to the New York Heart Association classification before the sCAP
  • Group A (healthy controls)
  • Presence of two or more comorbidities
  • Limited chance of survival for at least six months due to co-existing comorbidity (-ies) according to the judgement of the attending physicians
  • Pregnancy or lactation; Group B (CVRD controls)
  • Limited chance of survival for at least six months due to co-existing comorbidity (-ies) according to the judgement of the attending physicians
  • Limited chance of survival for at least six months due to co-existing comorbidity (-ies) according to the judgement of the attending physicians
  • Pregnancy or lactation; Group D (sCAP survivors)
  • Limited chance of survival for at least six months due to co-existing comorbidity (-ies) according to the judgement of the attending physicians
  • Pregnancy or lactation

Ennek a vizsgálatnak nincs helyszíne itt: Egyesült Államok.

Egy országban van helyszíne. Válassz országot, hogy lásd a helyszíneket.

A vizsgálatról

Mit akar kideríteni a vizsgálat

Pneumonia, which can be acquired in the community (including influenza and COVID-19), is a leading cause of mortality. The risk of severe cardiovascular diseases events (stroke, myocardial infarction, pulmonary embolism) increases after infections, but causal mechanisms are not understood yet. There is an essential need for improved understanding of the relationship between pneumonia and cardiovascular diseases and early identification of patients at risk of cardiovascular events to develop tailored therapies.

A teljes eredeti leírásKevesebb

The overall concept underpinning "Homi-lung" is to investigate the time course of host-microbiome interactions during \& after pneumonia to i) understand the causal relationship between trained immunity, microbiome dysbiosis and cardiovascular and respiratory diseases (CVRD) progressions, ii) define endotypes of pneumonia associated with response to treatment \& CVRD history; iii) develop biomarkers to predict the individual response to the treatment \& CVRD progression, and iv) preclinically validate therapeutical approaches for CVRD during \& after pneumonia.

A vizsgálat 4 csoportja

  • Healthy controls

    Controls with no or one comorbidity, predisposing to significant CV events and without a medical history of severe pneumonia.

    Kezelés: Blood samples and Oropharyngeal swab

  • CVRD controls

    Controls with comorbidities predisposing to major CV events and without a medical history of severe pneumonia

    Kezelés: Blood samples and Oropharyngeal swab és Six-minute walk test, Spirometry, ECG, Heart ultrasound and cardiopulmonary exercise stress testing, Completion of questionnaires of symptoms

  • COVID-19 survivors

    Patients cured of acute COVID-19

    Kezelés: Blood samples and Oropharyngeal swab és Six-minute walk test, Spirometry, ECG, Heart ultrasound and cardiopulmonary exercise stress testing, Completion of questionnaires of symptoms

  • sCAP survivors

    Patients cured of severe community-acquired pneumonia

    Kezelés: Blood samples and Oropharyngeal swab és Six-minute walk test, Spirometry, ECG, Heart ultrasound and cardiopulmonary exercise stress testing, Completion of questionnaires of symptoms

Kérdések a vizsgálat csapatának

  1. Milyen gyakran kell bejárnom, és egy-egy alkalom mennyi ideig tart?
  2. Megtérítik az utazási költséget?
  3. Megtarthatom a saját orvosomat?
  4. Mi történik, ha ki akarok lépni?

Contact the study team: see the registry record → Contacts and Locations

Oldal nyomtatása az orvosomnak

Adatok és források

Regiszteradat
Szerepel a ClinicalTrials.gov-on.
Hivatalos cím
A Non-interventional, Prospective, Cross-sectional Study of Cardiovascular Disease Progression in Survivors of Community Acquired Pneumonia and Lung Infection by Sars-Cov-2
A regiszteradat frissítve
2026. november 6.